4U8Z
| Crystal structure of MST3 with a pyrrolopyrimidine inhibitor (PF-06447475) | Descriptor: | 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile, MANGANESE (II) ION, Serine/threonine-protein kinase 24 | Authors: | Jasti, J, Song, X, Griffor, M, Kurumbail, R.G. | Deposit date: | 2014-08-05 | Release date: | 2015-03-18 | Last modified: | 2023-09-27 | Method: | X-RAY DIFFRACTION (1.63 Å) | Cite: | Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J.Med.Chem., 58, 2015
|
|
8Y22
| FGFR1 kinase domain with a covalent inhibitor 9g | Descriptor: | Fibroblast growth factor receptor 1, SULFATE ION, ~{N}-[4-[[4-azanyl-3-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]phenyl]propanamide | Authors: | Chen, X.J, Chen, Y.H. | Deposit date: | 2024-01-25 | Release date: | 2024-06-26 | Method: | X-RAY DIFFRACTION (2.792 Å) | Cite: | Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors. Eur.J.Med.Chem., 275, 2024
|
|
8XZ7
| FGFR1 kinase domain with a covalent inhibitor 10h | Descriptor: | 5-azanyl-3-[2-[4,6-bis(fluoranyl)-2-methyl-3~{H}-benzimidazol-5-yl]ethynyl]-1-[[3-(prop-2-enoylamino)phenyl]methyl]pyrazole-4-carboxamide, Fibroblast growth factor receptor 1, SULFATE ION | Authors: | Chen, X.J, Chen, Y.H. | Deposit date: | 2024-01-20 | Release date: | 2024-06-26 | Method: | X-RAY DIFFRACTION (1.75 Å) | Cite: | Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors. Eur.J.Med.Chem., 275, 2024
|
|
7FJD
| Cryo-EM structure of a membrane protein(WT) | Descriptor: | CHOLESTEROL, T cell receptor alpha variable 12-3,Possible J 11 gene segment,T cell receptor alpha chain constant, T cell receptor beta variable 6-5,M1-specific T cell receptor beta chain,T cell receptor beta constant 2, ... | Authors: | Chen, Y, Zhu, Y, Gao, W, Zhang, A, Guo, C, Huang, Z. | Deposit date: | 2021-08-03 | Release date: | 2022-07-27 | Method: | ELECTRON MICROSCOPY (3.2 Å) | Cite: | Cholesterol inhibits TCR signaling by directly restricting TCR-CD3 core tunnel motility. Mol.Cell, 82, 2022
|
|
7FJE
| Cryo-EM structure of a membrane protein(LL) | Descriptor: | CHOLESTEROL, T cell receptor alpha variable 12-3,Possible J 11 gene segment,T cell receptor alpha chain constant, T cell receptor beta variable 6-5,M1-specific T cell receptor beta chain,T cell receptor beta constant 2, ... | Authors: | Chen, Y, Zhu, Y, Gao, W, Zhang, A, Guo, C, Huang, Z. | Deposit date: | 2021-08-03 | Release date: | 2022-07-27 | Method: | ELECTRON MICROSCOPY (3 Å) | Cite: | Cholesterol inhibits TCR signaling by directly restricting TCR-CD3 core tunnel motility. Mol.Cell, 82, 2022
|
|
7FJF
| Cryo-EM structure of a membrane protein(CS) | Descriptor: | CHOLEST-5-EN-3-YL HYDROGEN SULFATE, T cell receptor alpha variable 12-3,Possible J 11 gene segment,T cell receptor alpha chain constant, T cell receptor beta variable 6-5,M1-specific T cell receptor beta chain,T cell receptor beta constant 2, ... | Authors: | Chen, Y, Zhu, Y, Gao, W, Zhang, A, Guo, C, Huang, Z. | Deposit date: | 2021-08-03 | Release date: | 2022-07-27 | Method: | ELECTRON MICROSCOPY (3.1 Å) | Cite: | Cholesterol inhibits TCR signaling by directly restricting TCR-CD3 core tunnel motility. Mol.Cell, 82, 2022
|
|
8HOG
| Crystal structure of Bcl-2 in complex with sonrotoclax | Descriptor: | Apoptosis regulator Bcl-2, ~{N}-[4-[(4-methyl-4-oxidanyl-cyclohexyl)methylamino]-3-nitro-phenyl]sulfonyl-4-[2-[(2~{S})-2-(2-propan-2-ylphenyl)pyrrolidin-1-yl]-7-azaspiro[3.5]nonan-7-yl]-2-(1~{H}-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide | Authors: | Liu, J, Xu, M, Feng, Y, Hong, Y, Liu, Y. | Deposit date: | 2022-12-10 | Release date: | 2024-01-17 | Last modified: | 2024-05-15 | Method: | X-RAY DIFFRACTION (1.8 Å) | Cite: | Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy. Blood, 143, 2024
|
|
8HOH
| Crystal structure of Bcl-2 G101V in complex with sonrotoclax | Descriptor: | Apoptosis regulator Bcl-2, ~{N}-[4-[(4-methyl-4-oxidanyl-cyclohexyl)methylamino]-3-nitro-phenyl]sulfonyl-4-[2-[(2~{S})-2-(2-propan-2-ylphenyl)pyrrolidin-1-yl]-7-azaspiro[3.5]nonan-7-yl]-2-(1~{H}-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide | Authors: | Liu, J, Xu, M, Feng, Y, Hong, Y, Liu, Y. | Deposit date: | 2022-12-10 | Release date: | 2024-01-17 | Last modified: | 2024-05-15 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy. Blood, 143, 2024
|
|
8HOI
| Crystal structure of Bcl-2 D103Y in complex with sonrotoclax | Descriptor: | Apoptosis regulator Bcl-2, FORMIC ACID, ~{N}-[4-[(4-methyl-4-oxidanyl-cyclohexyl)methylamino]-3-nitro-phenyl]sulfonyl-4-[2-[(2~{S})-2-(2-propan-2-ylphenyl)pyrrolidin-1-yl]-7-azaspiro[3.5]nonan-7-yl]-2-(1~{H}-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide | Authors: | Liu, J, Xu, M, Feng, Y, Hong, Y, Liu, Y. | Deposit date: | 2022-12-10 | Release date: | 2024-01-17 | Last modified: | 2024-05-15 | Method: | X-RAY DIFFRACTION (2.25 Å) | Cite: | Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy. Blood, 143, 2024
|
|
8HTR
| Crystal structure of Bcl2 in complex with S-9c | Descriptor: | 4-[4-[(2~{S})-2-(2-chlorophenyl)pyrrolidin-1-yl]phenyl]-~{N}-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1~{H}-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide, Apoptosis regulator Bcl-2 | Authors: | Liu, J, Xu, M, Feng, Y, Liu, Y. | Deposit date: | 2022-12-21 | Release date: | 2024-05-15 | Last modified: | 2024-06-05 | Method: | X-RAY DIFFRACTION (1.6 Å) | Cite: | Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2. J.Med.Chem., 67, 2024
|
|
8HTS
| Crystal structure of Bcl2 in complex with S-10r | Descriptor: | 4-[2-[(2~{S})-2-(2-cyclopropylphenyl)pyrrolidin-1-yl]-7-azaspiro[3.5]nonan-7-yl]-~{N}-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1~{H}-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide, Apoptosis regulator Bcl-2 | Authors: | Liu, J, Xu, M, Feng, Y, Liu, Y. | Deposit date: | 2022-12-21 | Release date: | 2024-05-15 | Last modified: | 2024-06-05 | Method: | X-RAY DIFFRACTION (1.25 Å) | Cite: | Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2. J.Med.Chem., 67, 2024
|
|
7XNS
| SARS-CoV-2 Omicron BA.2.12.1 variant spike | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Spike glycoprotein | Authors: | Wang, X, Wang, L. | Deposit date: | 2022-04-29 | Release date: | 2022-07-13 | Last modified: | 2024-07-17 | Method: | ELECTRON MICROSCOPY (3.48 Å) | Cite: | BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature, 608, 2022
|
|
7XIY
| SARS-CoV-2 Omicron BA.3 variant spike | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Spike glycoprotein | Authors: | Wang, X, Wang, L. | Deposit date: | 2022-04-14 | Release date: | 2022-07-13 | Last modified: | 2022-08-31 | Method: | ELECTRON MICROSCOPY (3.07 Å) | Cite: | BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature, 608, 2022
|
|
7XIX
| SARS-CoV-2 Omicron BA.2 variant spike (state 2) | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Spike glycoprotein | Authors: | Wang, X, Wang, L. | Deposit date: | 2022-04-14 | Release date: | 2022-07-13 | Last modified: | 2022-08-31 | Method: | ELECTRON MICROSCOPY (3.25 Å) | Cite: | BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature, 608, 2022
|
|
7XNQ
| SARS-CoV-2 Omicron BA.4 variant spike | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Spike glycoprotein | Authors: | Wang, X, Wang, L. | Deposit date: | 2022-04-29 | Release date: | 2022-07-13 | Last modified: | 2022-08-31 | Method: | ELECTRON MICROSCOPY (3.52 Å) | Cite: | BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature, 608, 2022
|
|
7XIW
| SARS-CoV-2 Omicron BA.2 variant spike (state 1) | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Spike glycoprotein | Authors: | Wang, X, Wang, L. | Deposit date: | 2022-04-14 | Release date: | 2022-07-13 | Last modified: | 2022-08-31 | Method: | ELECTRON MICROSCOPY (3.62 Å) | Cite: | BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature, 608, 2022
|
|
7XIZ
| SARS-CoV-2 Omicron BA.3 variant spike (local) | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Spike protein S1 | Authors: | Wang, X, Wang, L. | Deposit date: | 2022-04-14 | Release date: | 2022-07-13 | Last modified: | 2022-08-31 | Method: | ELECTRON MICROSCOPY (3.74 Å) | Cite: | BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature, 608, 2022
|
|
7XNR
| SARS-CoV-2 Omicron BA.2.13 variant spike | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Spike glycoprotein | Authors: | Wang, X, Wang, L. | Deposit date: | 2022-04-29 | Release date: | 2022-07-13 | Last modified: | 2022-08-31 | Method: | ELECTRON MICROSCOPY (3.49 Å) | Cite: | BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature, 608, 2022
|
|
7X6A
| |
7WRO
| Local structure of BD55-3372 and delta spike | Descriptor: | 3372H, 3372L, Spike protein S1 | Authors: | Liu, P.L. | Deposit date: | 2022-01-27 | Release date: | 2022-06-22 | Last modified: | 2022-08-31 | Method: | ELECTRON MICROSCOPY (3.4 Å) | Cite: | BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature, 608, 2022
|
|
7WR8
| |
7WRL
| |
7WRZ
| Local resolution of BD55-5840 Fab and SARS-COV2 Omicron RBD | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, BD55-5840H, BD55-5840L, ... | Authors: | Zhang, Z.Z, Xiao, J.J. | Deposit date: | 2022-01-28 | Release date: | 2022-06-22 | Last modified: | 2022-08-31 | Method: | ELECTRON MICROSCOPY (3.26 Å) | Cite: | BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature, 608, 2022
|
|
8H3T
| The crystal structure of AlpH | Descriptor: | AlpH, GLYCEROL | Authors: | Zhao, Y, Li, M, Jiang, M, Pan, L.F. | Deposit date: | 2022-10-09 | Release date: | 2023-09-13 | Last modified: | 2024-02-14 | Method: | X-RAY DIFFRACTION (1.866 Å) | Cite: | O-methyltransferase-like enzyme catalyzed diazo installation in polyketide biosynthesis. Nat Commun, 14, 2023
|
|
7DTZ
| FGFR4 complex with a covalent inhibitor | Descriptor: | Fibroblast growth factor receptor 4, N-[2-[[5-[[2,6-bis(chloranyl)-3,5-dimethoxy-phenyl]methoxy]pyrimidin-2-yl]amino]-3-methyl-phenyl]-2-fluoranyl-prop-2-enamide, SULFATE ION | Authors: | Chen, X.J, Dai, S.Y, Chen, Y.H. | Deposit date: | 2021-01-07 | Release date: | 2021-04-14 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.01 Å) | Cite: | Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors. Acs Med.Chem.Lett., 12, 2021
|
|